Barrington raised the firm's price target on Lifecore to $6.50 from $6 and keeps an Outperform rating on the shares after the company said it signed a new agreement with a global pharmaceutical company. This marks the second such agreement in two weeks, the analyst tells investors in a research note. Barrington believes the company has proven it can materially expand its clinical reach and execute against its strategic vision.
